Updates of European clinical trials in hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancers_West China Medical Journal

Authors：

CHEN Xinzu ¹ , ZHOU Zongguang ² ,  HU Jiankun ¹

1. Department of Gastrointestinal Surgery & Laboratory of Gastric Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Department of Gastrointestinal Surgery & Laboratory of Digestive Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

HU Jiankun, Email: hujkwch@126.com

Keywords：

Gastric cancer; Colorectal cancer; Hyperthermic intraperitoneal chemotherapy; Cytoreductive surgery; Clinical trial

DOI：

10.7507/1002-0179.201812082

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used in clinical setting, and is one of the optional treatment for peritoneal surface tumors. It can be used as adjuvant therapy to prevent peritoneal recurrence after gastric or colorectal cancer resection, or to treat those diseases with peritoneal metastasis alone through cytoreductive surgery +HIPEC or HIPEC alone, based on a multidisciplinary model. The updates of European HIPEC-related clinical trials, GASTRIPEC, GASTRICHIP, PRODIGE 7, PROPHYLOCHIP, COLOPEC, COMBATAC, were reported at the 11^th International Workshop on Peritoneal Surface Malignancy. In those trials, there was no definitive result surporting that HIPEC treatment might bring survival benefits to patients with gastric or colorectal cancer. However, long-term follow-up results remain to be seen, and some studies are still recruiting. Although several studies were designed as phase Ⅲ trials, the overall sample size was small-scaled. In addition, in the trials, diagnostic laparoscopy were widely used in gastric or colorectal cancer patients, which was helpful to improve staging accuracy and optimizing treatment strategies. The indications for HIPEC therapy (peritoneal cancer index) and technical issues (duration, temperature, approach, and agents) need further investigate.

Citation： CHEN Xinzu, ZHOU Zongguang, HU Jiankun. Updates of European clinical trials in hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancers. West China Medical Journal, 2018, 33(12): 1460-1465. doi: 10.7507/1002-0179.201812082 Copy

1.	Chen XZ, Liu Y, Wang R, et al. Improvement of cancer control in mainland China: epidemiological profiles during the 2004-10 National Cancer Prevention and Control Program. Lancet, 2016, 388(Suppl 1): S40.
2.	Wang R, Chen XZ. High mortality from hepatic, gastric and esophageal cancers in mainland China: 40 years of experience and development. Clin Res Hepatol Gastroenterol, 2014, 38(6): 751-756.
3.	Chen XZ, Zhang WH, Hu JK. A difficulty in improving population survival outcome of gastric cancer in mainland China: low proportion of early diseases. Med Oncol, 2014, 31(12): 315.
4.	Chen XZ, Hu JK, Zhou ZG. Importance of organized screening and surveillance for colorectal cancer in China: epidemiological differences from Europe. Eur J Cancer Prev, 2015, 24(6): 459-460.
5.	Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol, 1989, 16(4 Suppl 6): 83-97.
6.	Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?. Lancet Oncol, 2006, 7(1): 69-76.
7.	Desiderio J, Chao J, Melstrom L, et al. The 30-year experienced—A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer, 2017, 79: 1-14.
8.	Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a Meta-analysis. Ann Surg, 2016, 263(6): 1102-1111.
9.	Pinto A, Eveno C, Pocard M. Update on clinical trials in colorectal cancer peritoneal metastasis. Int J Hyperthermia, 2017, 33(5): 543-547.
10.	Rau B. Prospective multicentric phase Ⅲ study. Z Gastroenterol, 2014, 52(3): 262.
11.	Chen XZ, Yang K, Liu J, et al. Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer. World J Gastroenterol, 2011, 17(40): 4542-4544.
12.	Yonemura Y, Elnemr A, Endou Y, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol, 2012, 2012: 148420.
13.	Brandl A, Pachmayr E, Guel-Klein S, et al. Surgical treatment of peritoneal metastases of gastric cancer. Chirurg, 2018, 89(9): 669-677.
14.	Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase Ⅲ study. BMC Cancer, 2014, 14: 183.
15.	Quenet F, Elias D, Roca L, et al. A UNICANCER phase Ⅲ trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol, 2018, 36(18_Suppl): LBA3503.
16.	Desolneux G, Maziere C, Vara J, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS One, 2015, 10(3): e0122816.
17.	Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road?. Eur J Surg Oncol, 2018. https://doi.org/10.1016/j.ejso.2018.10.542.
18.	Klaver C, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer, 2015, 15(1): 428.
19.	Glockzin G, Rochon J, Arnold D, et al. A prospective multicenter phase Ⅱ study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer, 2013, 13: 67.
20.	Glockzin G, Zeman F, Croner RS, et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC trial. Clin Colorectal Cancer, 2018, 17(4): 285-296.

1. Chen XZ, Liu Y, Wang R, et al. Improvement of cancer control in mainland China: epidemiological profiles during the 2004-10 National Cancer Prevention and Control Program. Lancet, 2016, 388(Suppl 1): S40.
2. Wang R, Chen XZ. High mortality from hepatic, gastric and esophageal cancers in mainland China: 40 years of experience and development. Clin Res Hepatol Gastroenterol, 2014, 38(6): 751-756.
3. Chen XZ, Zhang WH, Hu JK. A difficulty in improving population survival outcome of gastric cancer in mainland China: low proportion of early diseases. Med Oncol, 2014, 31(12): 315.
4. Chen XZ, Hu JK, Zhou ZG. Importance of organized screening and surveillance for colorectal cancer in China: epidemiological differences from Europe. Eur J Cancer Prev, 2015, 24(6): 459-460.
5. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol, 1989, 16(4 Suppl 6): 83-97.
6. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?. Lancet Oncol, 2006, 7(1): 69-76.
7. Desiderio J, Chao J, Melstrom L, et al. The 30-year experienced—A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer, 2017, 79: 1-14.
8. Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a Meta-analysis. Ann Surg, 2016, 263(6): 1102-1111.
9. Pinto A, Eveno C, Pocard M. Update on clinical trials in colorectal cancer peritoneal metastasis. Int J Hyperthermia, 2017, 33(5): 543-547.
10. Rau B. Prospective multicentric phase Ⅲ study. Z Gastroenterol, 2014, 52(3): 262.
11. Chen XZ, Yang K, Liu J, et al. Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer. World J Gastroenterol, 2011, 17(40): 4542-4544.
12. Yonemura Y, Elnemr A, Endou Y, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol, 2012, 2012: 148420.
13. Brandl A, Pachmayr E, Guel-Klein S, et al. Surgical treatment of peritoneal metastases of gastric cancer. Chirurg, 2018, 89(9): 669-677.
14. Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase Ⅲ study. BMC Cancer, 2014, 14: 183.
15. Quenet F, Elias D, Roca L, et al. A UNICANCER phase Ⅲ trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol, 2018, 36(18_Suppl): LBA3503.
16. Desolneux G, Maziere C, Vara J, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS One, 2015, 10(3): e0122816.
17. Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road?. Eur J Surg Oncol, 2018. https://doi.org/10.1016/j.ejso.2018.10.542.
18. Klaver C, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer, 2015, 15(1): 428.
19. Glockzin G, Rochon J, Arnold D, et al. A prospective multicenter phase Ⅱ study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer, 2013, 13: 67.
20. Glockzin G, Zeman F, Croner RS, et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC trial. Clin Colorectal Cancer, 2018, 17(4): 285-296.

West China Medical Journal

Updates of European clinical trials in hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancers

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content